Drug intelligence / Profile preview

BW-00112

Development stage: Phase 2
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BW-00112 is a small interfering RNA (siRNA) therapeutic under development by Shanghai Argo Pharmaceutical (also known as Argo Biopharma) for the treatment of severe hypertriglyceridemia, mixed dyslipidemia, and dyslipidemia caused by low-density lipoprotein (LDL) cholesterol. The drug acts via RNA interference targeting apolipoprotein C3 to reduce triglyceride levels. It is administered subcutaneously and is currently in Phase II clinical trials for these indications[1][2][3].

Targets

APOC3 (Apolipoprotein C-III)

Beyond the preview

Go deeper on BW-00112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-00112.

Explore the full profile